Midlife cholesterol level and dementia 32 years later
Is there a risk?
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Interest has increased over the past decade in the hypothesis that risk factors experienced in childhood, young adulthood, or middle age contribute to late-life dementia. Such a view opens up new hope for primary prevention, which relies on effective modification of risk factors before the development of irreversible subclinical pathology. Since neurodegenerative pathology underlying dementia is initiated decades before clinical symptoms appear, primary prevention of dementia might be effectively targeted at risk factors in younger and middle-aged adults, whereas in older persons, prevention is most likely to be deemed successful if symptoms are delayed. Any evidence that modifiable early and midlife factors, such as cholesterol level, influence late life-dementia offers the greatest hope for primary prevention.
In this issue, Mielke et al.1 present results from a unique study of dementia in 5 birth cohorts of Swedish women, aged 38–60 years in 1968, followed for 32 years. The study focuses on the association between total cholesterol in midlife and dementia in late life. Midlife total cholesterol had no association with development of dementia, but decline over 32 years in 5 measures of total cholesterol was associated with increased dementia risk.
Many …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
Serum cholesterol and risk of Alzheimer diseaseA community-based cohort studyG. Li, J. B. Shofer, W. A. Kukull et al.Neurology, October 10, 2005 -
Articles
Serum cholesterol changes after midlife and late-life cognitionTwenty-one-year follow-up studyA. Solomon, I. Kåreholt, T. Ngandu et al.Neurology, March 05, 2007 -
Articles
Midlife cardiovascular risk factors and risk of dementia in late lifeR. A. Whitmer, S. Sidney, J. Selby et al.Neurology, January 24, 2005 -
Articles
Midlife vascular risk factors and late-life mild cognitive impairmentA population-based studyM. Kivipelto, E.-L. Helkala, T. Hänninen et al.Neurology, June 26, 2001